Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells

J. Dovedi, Simon; J. Elder, Matthew; Yang, Chunning; I. Sitnikova, Suzanne; Irving, Lorraine; M. Hansen, Anna; Hair, James; C. Jones, Des; Hasani, Sumati; Wang, Bo; Im, Seock‐Ah; Tran, Ben; S. Subramaniam, Deepa; D. Gainer, Shelby; Vashisht, Kapil; Lewis, Arthur; Jin, Xiaofang; Kentner, Stacy; Mulgrew, Kathy; Wang, Yaya; G. Overstreet, Michael; Dodgson, James; Wu, Yanli; Palazón, Asís; Morrow, Michelle; Jonah Rainey, G.; J. Browne, Gareth; Neal, Frances; V. Murray, Thomas; Tołoczko, Aleksandra; F. Dall’Acqua, William; Achour, Ikbel; J. Freeman, Daniel; W. Wilkinson, Robert; Mazor, Yariv

doi:10.1158/2159-8290.cd-20-1445

Public

Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells

Published in Cancer Discovery • Jan 8, 2021

Authors:

Simon J. Dovedi

Matthew J. Elder

Chunning Yang

Abstract

Abstract The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent bispecific antibody designed to suppress...

Subject

Blockade

Bispecific antibody

PD-L1

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!